05.08.06
Bristol-Myers Squibb received approval for its sBLA for the licensure of Lonza Biologics to support increased production capacity for Orencia, enabling the company to meet expected long-term demand. This follows the December 2005, FDA approval of Orencia for the treatment of rheumatoid arthritis (RA).
Orencia is indicated for reducing signs and symptoms, inducing major clinical response, slowing the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs).
Orencia is indicated for reducing signs and symptoms, inducing major clinical response, slowing the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs).